No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BMRN240517C85000
- 0.17
- +0.04+30.77%
15min DelayClose May 15 16:00 ET
0.30High0.17Low
0.20Open0.13Pre Close118 Volume956 Open Interest85.00Strike Price2.36KTurnover55.61%IV5.88%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.17Time Value100Contract SizeAmericanOptions Type0.0860Delta0.0489Gamma643.20Leverage Ratio-0.1071Theta0.0004Rho55.34Eff Leverage0.0091Vega
Intraday
- 5D
- 1D
News
Express News | Third Point LLC - Change in Holdings Are as of March 31, 2024 and Compared With the Previous Quarter Ended as of December 31, 2023
Express News | Third Point LLC Dissolves Share Stake in Biomarin Pharmaceutical Inc
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.
Express News | BioMarin Pharmaceutical To Cut About 170 Employees
Express News | Biomarin Pharmaceutical Inc: Workforce Reductions Are Expected to Be Substantially Completed by End of July 2024
Express News | Biomarin Pharmaceutical Inc: Estimates That It Will Incur Aggregate Pre-Tax Charges of Approximately $15 - $20 Mln During Q2 of 2024
Comments
Recent insider selling at BioMarin Pharmaceutical raises caution despite high insider ownership. The history of share sales is concerning, though the company's earnings growth is positive.
Insiders At BioMarin Pharmaceutical Sold US$6.7m In Stock, Alluding To Potential Weakness 1
BioMarin's CEO, Alexander Hardy, expressed confidence in Hubbard's leadership and expertise in lifecycle management and delivering growth across multiple therapeutic areas. He anticipates that her deep experience in the biopharmaceutical industry will add to the talent within the organization.
BioMarin Pharmaceutical Inc.'s low P/S ratio may be due to its sluggish growth forecast. The market's expectation of continued poor revenue growth could be suppressing the P/S. Shareholders' pessimism on the company's revenue prospects seems to be the main contributor to the depressed P/S.
1
BioMarin Pharmaceutical's decent earnings growth and high rate of reinvestment are positive, despite low ROE. However, earnings growth could have been higher with improved ROE. Forecasts reveal expected earnings acceleration.
Analysts see M&A as integral to BioMarin's value creation. Clarity on the market potential of Roctavian could stimulate transactional activities. A gene therapy division spin-off followed by a business sale is anticipated.
Read more